Humacyte (NASDAQ:HUMA) Given “Buy” Rating at D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $25.00 target price on the stock.

Several other analysts have also issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Benchmark upped their price objective on shares of Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Humacyte presently has an average rating of “Buy” and an average price target of $13.71.

Humacyte Stock Down 5.6 %

Shares of NASDAQ:HUMA opened at $3.04 on Wednesday. The stock has a market cap of $382.61 million, a price-to-earnings ratio of -2.27 and a beta of 1.30. The business’s 50 day moving average is $4.39 and its 200 day moving average is $5.01. Humacyte has a 12-month low of $2.81 and a 12-month high of $9.97.

Institutional Trading of Humacyte

Several hedge funds have recently added to or reduced their stakes in the stock. Woodline Partners LP grew its position in shares of Humacyte by 235.7% during the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock valued at $14,386,000 after acquiring an additional 2,000,268 shares during the period. State Street Corp lifted its stake in Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares during the last quarter. CenterBook Partners LP bought a new position in Humacyte during the fourth quarter valued at $6,463,000. Brevan Howard Capital Management LP grew its stake in shares of Humacyte by 2,795.1% during the 4th quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock worth $4,426,000 after acquiring an additional 846,070 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Humacyte by 10.8% in the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock worth $28,294,000 after purchasing an additional 543,995 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.